

arGEN-X announces results of Annual General Meeting 2015

Breda, the Netherlands / Ghent, Belgium, 13 May 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.

Voting results

The results of the votes will be posted shortly on the Company's website www.argen-x.com/shareholders-meeting

Changes to the board of directors

As previously announced, Dr. H. van Barlingen and Dr. B. Montanari have resigned from the board of directors as non-executive directors with effect as per the date of the meeting, to be replaced by independent industry professionals in line with the Dutch Corporate Governance Code.

Mr. Donald (Don) deBethizy was appointed as non-executive director to the board. Don has 30 years of experience in research and development, financial, business, and operating management in the biotechnology and consumer products industry. Don is currently President of White City Consulting ApS in Denmark. He served as President and CEO of Santaris Pharma A/S, Denmark and USA until September 2014 when the Company was sold to Roche.

Adoption of 2014 financial statements

Furthermore, the Company's financial statements for the 2014 financial year were adopted by the shareholder meeting. The 2014 Annual report and Accounts are available to shareholders in the 'Investor' section of the Company's website at www.argen-x.com. Paper copies are available upon request to the Company.

About arGEN-X

arGEN-X combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.

www.argen-X.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 243 40 70
info@arGEN-X.com

Mark Swallow/David Dible
Citigate Dewe Rogerson
+44 207 282 2948
arGEN-X@citigatedr.co.uk

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X' actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"